Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

AARD Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 21.82M shares rose 0.6% year over year, in line with the +1.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.6% toward the trailing-twelve-month pace of +1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.82M+0.0% QoQ
Last fiscal yearDec 2025
21.82M+0.6% YoY
LTMMar 2026
21.77M+1.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%——
1 year+0.6%——
3-year CAGR+0.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
21.82M USD
Year-over-year change
+0.6%
3-year CAGR
+0.7%

Weighted Avg Shares vs competitors

How AARD compares with its peers on the latest reported figures

  • AARD's LTM Mar 2026 weighted avg shares of 21.77M shares is the 8th highest of the 11 companies compared; the peer median is 63.58M shares.
  • Its year-over-year change of +1.1% is the 9th highest of 11, against a peer median of +16.4%.
  • Over three fiscal years its annual growth of +0.7% compares with a peer median of +25.5%.
AARD Competitors Peer median
Weighted Avg Shares for AARD and competitors
Company Period LTM YoY 3-year CAGR
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202644.51M +24.9%+27.5%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 202621.77M +1.1%+0.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding AARD) 63.58M+16.4%+25.5%

Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development7.17M4.48M17.36M48.94M
Selling, General & Admin2.7M2.17M5.31M13.79M
Operating Expenses11.36M7.42M22.79M62.73M
Depreciation & Amortization110K97K16K36K
EBITDA(10.76M)(6.56M)(22.65M)(57.56M)
EBITDA Margin————
Operating Income(11.36M)(7.42M)(22.79M)(62.73M)
Operating Margin————
Interest Income120K1.42M2.41M5.14M
Interest Expense0000
Other Income / Expenses(2.2M)207K2.2M5.13M
Income Before Tax(13.56M)(7.21M)(20.59M)(57.59M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Net Margin————
EPS (Basic)(0.63)(0.34)(0.95)(2.64)
EPS (Diluted)(0.63)(0.34)(0.95)(2.64)
Weighted Avg Shares21.38M21.38M21.7M21.82M
Weighted Avg Shares (Diluted)21.38M21.38M21.7M21.82M

Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Intrinsic Alpha fair value

Locked

Current Price

$3.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.